Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis

Nephron - Clinical Practice

Volumn 102, Issue 3-4, 2006, Pages

  Koukoulaki, Maria ^a   Jayne, David R W ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Efficacy; Mycophenolate mofetil; Systemic vasculitis; Tolerability

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ALOPECIA; ANCA ASSOCIATED VASCULITIS; ARTICLE; CELLULITIS; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; EYE INFLAMMATION; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GINGIVITIS; HEADACHE; HERPES ZOSTER; HUMAN; INFECTION; INSOMNIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MENTAL CONCENTRATION; MENTAL DISEASE; MYCOSIS; NAIL INFECTION; NAUSEA; PANCYTOPENIA; PHARYNGITIS; PRIORITY JOURNAL; RASH; RECTUM HEMORRHAGE; RECURRENCE RISK; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; VASCULITIS;

EID: 33344473052     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089667     Document Type: Article

References (24)

1. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR: Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776-784.
2. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
3. Langford CA, Talar-Williams C, Barron KS, Sneller MC: Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-469.
4. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K: High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002;47:326-332.
5. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ: Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999;10:1965-1971.
6. Langford CA, Talar-Williams C, Sneller MC: Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004;51:278-283.
7. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG: Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003;62:534-539.
8. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-1162.
9. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192.
10. Schmitt WH, Jayne DRW, van der Woode FJ, for the European Vasculitis Study Group (EUVAS): Mycophenolate mofetil (MMF) vs. azathioprine (AZA) for the maintenance of remission in ANCA-associated vasculitis: The IMPROVE Protocol. Kidney Blood Press Res 2003;26:295.
11. Stassen P, Cohen Tervaert JW, Stegeman CA: Induction of remission in active ANCA-associated vasculitis with mycophenolate mofetil. Kidney Blood Press Res 2003;26:292.
12. Sanquer S, Breil M, Baron C, Dahmane D, Astier A, Lang P: Trough blood concentrations in long-term treatment with mycophenolate mofetil. Lancet 1998;351:1557.
13. Neumann I, Haidinger M, Jager H, Grutzmacher H, Griesmacher A, Muller MM, Bayer PM, Meisl FT: Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003;14:721-727.
14. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA: Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10:833-839.
15. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61:1098-1114.
16. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B: Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003;75:1341-1346.
17. Maes B, Oellerich M, Ceuppens JL, Armstrong VW, Evenepoel P, Kuypers D, Messiaen T, Shipkova M, Wieland E, Vanrenterghem Y: A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrol Dial Transplant 2002;17:923-926.
18. Riskalla MM, Somers EC, Fatica RA, McCune WJ: Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1508-1512.
19. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C: Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39-47.
20. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, Savage C, Pusey C, Jayne D: Prospective study of TNF-α blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-721.
21. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-361.
22. Keogh KA, Wylam ME, Stone JH, Specks U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-268.
23. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993;341:1620-1622.
24. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, Peter HH, Kalden JR, Gobel U, Drexler JM, Hotta O, Nowack R, Van Der Woude FJ: 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-447.